hereditary angioedema - Search News

News

RNA, Hereditary Angioedema and FDA

Medpage Today on MSN · 16h

RNA-Targeted Drug Approved for Preventing Hereditary Angioedema Attacks

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly subcutaneously. Weeks later, regulators approved sebetralstat (Ekterly) as an oral, on-demand therapy for HAE.

The American Journal of Manag… · 19h

FDA Approves First RNA-Targeted Treatment for Hereditary Angioedema

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

The Pharma Letter · 2h

FDA approves Ionis’ Dawnzera as first RNA-targeted therapy for HAE

The US Food and Drug Administration (FDA) has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Ionis Wins Approval For First RNA-Targeted Prophylactic for Rare Swelling Disease

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

18h

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...

Stocktwits on MSN10h

Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy

Wall Street analysts boosted their targets on Ionis Pharmaceuticals after the FDA approved its RNA-based drug Dawnzera for ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results